At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
VAL201drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours
In Brief
A Phase 2 clinical trial evaluating VAL201 for Stage III Prostate Carcinoma and Stage IV Prostate Carcinoma. Completed, enrolled 12 participants.
Detailed Summary
Dose finding safety study of VAL201 in cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionJan 2020
TodayJul 2026
First PostedOct 31, 2014
Enrollment StartOct 1, 2014
Primary CompletionJan 27, 2020
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.7 years ago
Interventions
VAL201drug
VAL201-001 Sub-cutaneous injection.